Related references
Note: Only part of the references are listed.Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
Irene Man et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan
Satoshi Nakagawa et al.
CANCER SCIENCE (2020)
Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-TypeSpecific Effectiveness and Evidence of Cross-Protection
Risa Kudo et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV)
Penelope Gray et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
Melanie Drolet et al.
LANCET (2019)
Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction
Courtney Covert et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors
Petra J. Woestenberg et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)
Matti Lehtinen et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Evaluation of HPV type-replacement in unvaccinated and vaccinated adolescent females-Post-hoc analysis of a community-randomized clinical trial (II)
Penelope Gray et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E. Tota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Change in Human Papillomavirus Prevalence Among US Women Aged 18-59 Years, 2009-2014
Abbey B. Berenson et al.
OBSTETRICS AND GYNECOLOGY (2017)
Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials
Joseph E. Tota et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Outcomes for girls without HPV vaccination in Japan
Yusuke Tanaka et al.
LANCET ONCOLOGY (2016)
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013
Ross L. Cameron et al.
EMERGING INFECTIOUS DISEASES (2016)
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes
David Mesher et al.
EMERGING INFECTIOUS DISEASES (2016)
Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: An analysis using the kanagawa population-based cancer registry, 1975-2012
Yoko Motoki et al.
CANCER EPIDEMIOLOGY (2015)
HPV vaccination crisis in Japan
Sharon J. B. Hanley et al.
LANCET (2015)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon
Archana Chatterjee
EXPERT REVIEW OF VACCINES (2014)
Human Papillomavirus Genotype Distribution in Cervical Intraepithelial Neoplasia Grade 2/3 and Invasive Cervical Cancer in Japanese Women
Yukari Azuma et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Analytical performance of newly developed multiplex human papillomavirus genotyping assay using Luminex xMAP™ technology (Mebgen™ HPV Kit)
Satoru Ozaki et al.
JOURNAL OF VIROLOGICAL METHODS (2014)
Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
Sepehr N. Tabrizi et al.
LANCET INFECTIOUS DISEASES (2014)
Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women
Masayoshi Hosaka et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
HPV genotype replacement: too early to tell
Margarita Pons-Salort et al.
LANCET INFECTIOUS DISEASES (2013)
Clinical trials of human papillomavirus vaccines and beyond
Matti Lehtinen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer
Mamiko Onuki et al.
CANCER SCIENCE (2009)
Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years
Tino F. Schwarz et al.
VACCINE (2009)
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice
MJ Khan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Share Paper
